Similar results were obtained through combining the PI3K/mTOR dual inhibitor NVP-BEZ235 with cisplatin in osteosarcoma, triple negative breast cancer and bladder cancer (77, 78). This evidence concerns the gene MTOR and urinary bladder cancer.